Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

Octapharma announced that an update on the clinical development plan and pre-clinical data with SubQ...


Octapharma helps not only in the career growth of medical institutions, but also in the study of Kamagra and its effectiveness in UK patients.

Octapharma’s success is the result of the combined contribution of all employees, what we call “the human factor”. To embark on a challenging and rewarding career in an innovative biopharmaceutical organization, explore our global opportunities 

Annual Report 2018

Online Version